Cost-Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor Initiatives

American Journal of Transplantation

Volumn 4, Issue 4, 2004, Pages 569-573

  Whiting, James F ^a   Kiberd, Bryce ^b   Kalo, Zoltan ^c   Keown, Paul ^d   Roels, Leo ^e   Kierulf, Maria ^f  

^a MAINE MEDICAL CENTER   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Donor Action Foundation   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Organ donor; Renal transplantation

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; EVALUATION; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 1942532189     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00373.x     Document Type: Article

References (29)

1. Roels L, Wight C. Donor Action: an international initiative to alleviate organ shortage. Prog Transplant 2001; 11: 90-97.
2. Wight C, Cohen B, Roels L, Donor Action. A quality assurance programme for intensive care units which increases organ donation. J Intensive Care Med 2000; 15: 104-115.
3. deWit GA, Ramstein PG, deCharro FT. Economic evaluation of end-stage renal disease treatment. Health Policy 1998; 44: 213-233.
4. Eggers P. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 1992; 12: 284-289.
5. Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost utility of renal transplantation. Kidney Int 1996; 50: 235-242.
6. Whiting JF, Zavala EY, Cohen DS et al. Economic cost of expanded criteria donors in cadaveric renal transplantation: Analysis of Medicare payments. Transplantation 2000; 70: 755-760.
7. Roels L, Kalo Z, Boesebeck D, Whiting JF, Wight C. Cost-benefit approach for evaluating investment into Donor Action: the German case. Transplant Int 2003; 16: 321-326.
8. Birkmeyer JD, Liu JY. Decision analysis models: opening the black box. Surgery 2003; 133: 1-4.
9. Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002; 73: 616-622.
10. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2002; 134: 565-576.
11. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of lung transplantation. J Thoracic Cardio Surg 2003; 123: 411-418.
12. Ouwens JP, VanEnckevort PJ, TenVergert EM et al. The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands. Transplant Int 2003; 16: 123-127.
13. Coukell AJ, Plosker GL. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998; 14: 691-708.
14. Young M, Plosker GL. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation. Pharmacoeconomics 2002; 20: 675-713.
15. Walters SJ, Whitfield M, Akehurst RL, Chilcott JB. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Pharmacoeconomics 2003; 21: 129-138.
16. The Gallup Organization I. The American Public's Attitudes Towards Organ Donation and Transplantation. Boston, MA: The Partnership for Organ Donation, 1993.
17. Baxter D. Beyond Comparison: Canada's Organ Donation Rate in an International Context. Vancouver, British Columbia: The Urban Futures Institute, 2001.
18. Canadian Organ Replacement Registry 2001 Report, Vol. 2. Organ Donation and Transplantation. Canadian Institute for Health Information. Ottawa, Ontario, 2001.
19. Bosch X. Spain leads world in organ donation and transplantation. J Am Med Assoc 1999; 282: 70 7-7-.
20. Volpe JP. Organ and Tissue Donation: a Canadian Approach. Report of the Standing Committee on Health. Ottawa, Canada: Public Works and Government Services, 1999: 1-90.
21. Stogis S, Hirth RA, Strawderman RL, Banaszak-Holl J, Smith DG. Using a standardized donor ratio to assess the performance of organ procurement organizations. Health Serv Res 2002; 37: 1329-1344.
22. Whiting JF for the Transplant Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation. 2000; 70: 1115-1121.
23. Canadian Organ Replacement Registry, Vol. 1: Dialysis and Renal Transplantation. Ottawa, Ontario: Canadian Institute for Health Information, 2001.
24. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States. N Engl J Med 2000, 1988-96; 342: 605-612.
25. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
26. Meier-Kriesche H, Kaplan B. Death after graft loss: a novel endpoint for renal transplantation. Transplant Proc 2001; 33: 3405-3406.
27. Statistics Canada. Population Census 2002.
28. USRDS. Annual Report 2001. Bethesda, Maryland: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
29. Beck JR, Kassirer JP, Pauker SG, Gottlieb JE, Klein K. A convenient approximation of life expectancy. Am J Med 1982; 73: 883-897.